Wanbury Limited announced that its subsidiary, Wanbury Skin Health Limited, has launched the berrysoft™ baby product range across multiple states in India. This move marks a strategic entry into the paediatric dermatology segment, leveraging existing relationships with healthcare professionals.

The launch involves a portfolio of products designed for everyday baby skincare and hygiene. Four products have already been introduced to the market: Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, and Syndet Handwash. Three additional products, including Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream, are currently in the pipeline.

Regulatory approvals and market reach

To facilitate this multi-state launch, Wanbury Skin Health has secured necessary regulatory clearances. The company has received GST registration in five states, including Maharashtra, Delhi, and Karnataka, with three more states in the pipeline. Additionally, CFA Drug Licenses have been obtained in Mumbai, Jaipur, Patna, and Ambala, with four more licenses pending approval.

Strategic focus on paediatric dermatology

The initiative reflects a broader strategy to expand Wanbury’s healthcare portfolio through its subsidiaries. Wanbury Skin Health aims to cross-sell these new dermatological solutions to its established customer base. Currently, Wanbury markets cold and cough products to paediatricians, providing an existing channel to introduce the berrysoft range.

Beyond paediatricians, the company plans to build relationships with dermatologists to strengthen its presence in the general dermatology segment. The product formulations emphasize features such as skin-friendly pH, being 100% soap-free, and being dermatologically tested.

What the numbers show

While specific revenue figures for this new segment were not disclosed, the operational data highlights a focused geographic expansion strategy. The simultaneous acquisition of regulatory approvals in five key economic zones (Maharashtra, Delhi, Karnataka) suggests a prioritized rollout in high-density urban markets where branded infant care products have higher adoption rates. The pipeline of three additional SKUs indicates a phased approach to capturing the full daily skincare routine, rather than a single-product launch.

Wanbury Limited shareholders approved the adoption of audited financial statements for the fiscal year ended March 31, 2026, during the company's 38th Annual General Meeting held on September 24, 2026. The meeting also ratified the remuneration of the cost auditor and approved the re-appointment of key directors.

The proceedings were conducted via Video Conferencing/Other Audio Visual Means, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. K. Chandran, Whole-time Director, presided over the meeting. Independent Directors Dr. Anupama Vaidya, Mr. Mridul S. Mehta, Mr. P.V. Shankar Dass, and Mr. Manojkumar K. Gursahani were also present.

Key resolutions passed

All resolutions put forth for shareholder approval were passed with the requisite majority following remote e-voting. The specific items of business included:

• Adoption of Financial Statements: Ordinary resolution to adopt the Audited Financial Statements for FY26 along with the Reports of Directors and Auditors.
• Director Re-appointment: Ordinary resolution for the re-appointment of Mr. K. Chandran as Director liable to retire by rotation.
• Cost Auditor Remuneration: Ordinary resolution ratifying the remuneration payable to M/s. ABK & Associates, Cost Accountants, for conducting the cost audit for FY27.
• Special Resolution for WTD: Special resolution for the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director and continuation of his role beyond the age of 70 years.

Governance and voting process

Ms. Kala Agarwal, Practicing Company Secretary, was appointed as the Scrutinizer to conduct the remote e-voting process. The Scrutinizer's report confirmed that all resolutions were passed fairly and transparently. The Company Secretary confirmed that voting results would be available on the company website within 48 hours of the meeting's conclusion.

The meeting commenced at 11:30 am and concluded at 12:35 pm. Queries raised by members were addressed to their satisfaction.

Director and auditor details

The new disclosure provides specific details regarding the appointments ratified during the AGM. Mr. Mohan Kumar Rayana (DIN: 07878975) was re-appointed as Whole-time Director, with his tenure extended from August 21, 2026, to August 20, 2031. He holds a B. Pharm degree from the University of Mumbai and has over 25 years of experience with Wanbury in advisory roles, focusing on business strategy, talent enrichment, and mergers and acquisitions.

M/s. ABK & Associates, established in 1989, was ratified as the Cost Auditor for FY27. The firm has over 35 years of professional experience and serves clients across diverse industries including pharmaceuticals, automobiles, and engineering. Both the director and the auditing firm are not related to any other directors of the company and are not debarred from holding office by any regulatory authority.

Voting results breakdown

The scrutinizer's report detailed the voting patterns across promoter and public categories. While promoters voted unanimously in favor of all resolutions, public shareholders showed varying levels of support, particularly regarding the special resolution for the Whole-time Director's re-appointment.

What the numbers show

The voting data reveals a distinct divergence in shareholder sentiment regarding the special resolution for Mr. Mohan Kumar Rayana's re-appointment. While public non-institutional investors supported the move with 99.33% in favour, public institutional investors were split almost evenly, with 50.92% voting against the resolution. This contrasts sharply with the unanimous support from promoters and near-unanimous support from public shareholders for the routine adoption of financial statements and the re-appointment of Mr. K. Chandran. The overall vote in favour for the special resolution remained at 99.94% due to the significant weight of promoter votes, but the institutional dissent highlights a specific governance concern among professional investors regarding the continuation of the director beyond age 70.